Current AGITG trials in activation phase are:
Protocol Title: A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Study Chair: Dr Matthew Burge
Associate Oncology Program Manager: Cheryl Friend
Trial Coordinator: T.B.C.
Contact Email: firstname.lastname@example.org
Detailed information will be available shortly on: Australian and New Zealand Clinical Trials Registry
Trial Newsletter: None to date
- AGITG Innovation Fund ($100,000)
- Alan Bishop Fund ($20,000)
Design: A prospective randomised phase 2 study to assess the activity of panitumumab alone versus panitumumab plus 5FU as first line treatment for RAS wild type elderly patients with metastatic colorectal cancer
Key question: To evaluate the progression free survival and patient acceptability of both panitumumab alone and when given with 5FU as first line treatment in RAS wild type metastatic colorectal cancer.
To review the summary click here